Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine.

Abstract

Ras malignant transformation requires posttranslational modification by farnesyltransferase (FTase). Here we report on the design and antitumor activity, in monotherapy as well as in combination therapy with cytotoxic agents, of a novel class of non-thiol-containing peptidomimetic inhibitors of FTase and the closely related family member geranylgeranyltransferase I (GGTase I). The non-thiol-containing FTI-2148 is highly selective for FTase (IC50, 1.4 nM) over GGTase I (IC50, 1700 nM), whereas GGTI-2154 is highly selective for GGTase I (21 nM) over FTase (IC50, 5600 nM). In whole cells, the corresponding methylester prodrug FTI-2153 is >3000-fold more potent at inhibiting H-Ras (IC50, 10 nM) than Rap1A processing, whereas GGTI-2166 is over 100-fold more selective at inhibiting Rap1A (IC50, 300 nM) over H-Ras processing. Furthermore, FTI-2153 was highly effective at suppressing oncogenic H-Ras constitutive activation of mitogen-activated protein kinase and human tumor growth in soft agar. FTI-2148 suppressed the growth of the human lung adenocarcinoma A-549 cells in nude mice by 33, 67, and 91% in a dose-dependent manner. Combination therapy of FTI-2148 with either cisplatin, gemcitabine, or Taxol resulted in a greater antitumor efficacy than monotherapy. GGTI-2154 in similar antitumor efficacy experiments is less potent than FTI-2148 and inhibits tumor growth by 9, 27, and 46%. Combination therapy of GGTI-2154 with cisplatin, gemcitabine, or Taxol is also more effective. Finally, FTI-2148 and GGTI-2154 are 30- and 33-fold more selective and 30- and 16-fold more potent in whole cells than our previously reported thiol-containing FTI-276 and GGTI-297, respectively. Thus, our results demonstrate that this highly potent and selective novel class of non-thiol-containing peptidomimetics inhibits human tumor growth in whole animals and that combination therapy with cytotoxic agents is more beneficial than monotherapy.

• Authors: J Sun, M A Blaskovich, D Knowles, Y Qian, J Ohkanda, R D Bailey, A D Hamilton, S M Sebti
• Journal: Cancer research (Cancer Res) Vol. 59 Issue 19 Pg. 4919-26 (Oct 01 1999) ISSN: 0008-5472 [Print] United States
• PMID: 10519405 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents
• Benzamides
• Enzyme Inhibitors
• GGTI 297
• Oligopeptides
• Deoxycytidine
• Alkyl and Aryl Transferases
• geranylgeranyltransferase type-I
• Farnesyltranstransferase
• Mitogen-Activated Protein Kinases
• rap1 GTP-Binding Proteins
• ras Proteins
• Paclitaxel
• Cisplatin
• Gemcitabine

Topics

• 3T3 Cells
• Adenocarcinoma (drug therapy)
• Alkyl and Aryl Transferases (antagonists & inhibitors)
• Animals
• Antineoplastic Agents (administration & dosage, therapeutic use, toxicity)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use, toxicity)
• Benzamides (chemistry, therapeutic use, toxicity)
• Cell Division (drug effects)
• Cisplatin (administration & dosage, therapeutic use, toxicity)
• Deoxycytidine (administration & dosage, analogs & derivatives, therapeutic use, toxicity)
• Enzyme Inhibitors (administration & dosage, therapeutic use, toxicity)
• Farnesyltranstransferase
• Humans
• Lung Neoplasms (drug therapy)
• Mice
• Mice, Nude
• Mitogen-Activated Protein Kinases (drug effects)
• Molecular Structure
• Oligopeptides (chemistry)
• Paclitaxel (administration & dosage, therapeutic use, toxicity)
• Transplantation, Heterologous
• Tumor Cells, Cultured
• rap1 GTP-Binding Proteins (antagonists & inhibitors)
• ras Proteins (antagonists & inhibitors)
• Gemcitabine